Embrace Meeting - First Line Trials in post Menopausal Women

Speciality: Obstetrics and Gynecology


Speaker:

Dr. Chintan Shah - Moderator | Medical Oncologist HOC Vedanta

Dr. Murtaza Bohra - Case Presenter | Medical Oncologist National Cancer Institute

Dr. Ashish B. Agrawal - Expert Panelist | Medical Oncologist & Haematologist Kiran Multispecialty Hospital

Dr. Shivam Shingla - Expert Panelist | Medical Oncologist S L Raheja Hospital

Dr. Avinash Talele - Expert Panelist | Medical Oncologist Apollo Hospital

Description:

A warm welcome to all the medical professionals in this interesting session on Embrace Meeting - First Line Trials in post Menopausal Women 
The Embrace Meeting is a significant event that brings together experts to discuss the latest advancements in the treatment of postmenopausal women, focusing particularly on first-line clinical trials. This meeting provides a platform for sharing cutting-edge research, clinical experiences, and innovative strategies aimed at improving healthcare outcomes for this demographic.
 A key highlight of the Embrace Meeting is the discussion of first-line clinical trials specifically tailored for postmenopausal women. These trials explore the efficacy and safety of new therapeutic options in treating conditions prevalent in this group, such as osteoporosis, breast cancer, and cardiovascular disease. The aim is to identify optimal first-line treatments that offer the best balance of efficacy and tolerability.
These advancements represent potential game-changers in the management of health issues in postmenopausal women, offering hope for improved quality of life.
Therefore, get an overall knowledge of embrace meeting - first line trials in post menopuasal women
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot